A Delaware federal judge on Oct. 7 upheld Endo Pharmaceuticals Inc.’s patent for its opioid painkiller Opana ER, rejecting arguments by Amneal Pharmaceuticals and Teva Pharmaceuticals USA that the patent claim was invalid as obvious and that Teva had obtained permission to use its active ingredient.
In a 30-page trial opinion, U.S. District Judge Richard G. Andrews of the District of Delaware on Oct. 7 ruled that nothing in the prior art had taught how to manufacture oxymorphone with low levels of alpha, beta-unsaturated ketone, or ABUK, a compound that was discovered in 2002 to be linked to cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]